Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,003,273 papers from all fields of science
Search
Sign In
Create Free Account
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Known as:
Metastatic Non-Squamous Non-Small Cell Lung Cancer
A non-squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
14 relations
Chest
EGFR Gene Mutation
EGFR gene
Epithelial Cells
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR…
M. Reck
,
G. Shankar
,
+5 authors
A. Sandler
Expert Review of Respiratory Medicine
2019
Corpus ID: 209341176
ABSTRACT Introduction: Cancer immunotherapy has revolutionized the treatment of patients with advanced or metastatic non-small…
Expand
Highly Cited
2018
Highly Cited
2018
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC
M. McKeage
,
D. Kotasek
,
+8 authors
B. Hughes
Targeted oncology
2018
Corpus ID: 3509204
BackgroundDelta-like ligand 4-Notch (DLL4-Notch) signaling contributes to the maintenance of chemotherapy-resistant cancer stem…
Expand
2015
2015
Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer
Ji-Jie Huang
,
Shu-xiang Ma
,
+5 authors
Likun Chen
Chinese journal of cancer
2015
Corpus ID: 9983473
Toxic epidermal necrolysis (TEN) is a rare acute life-threatening mucocutaneous disorder that is mostly drug-related (80%–95…
Expand
2015
2015
Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first…
A. Kotsakis
,
N. Kentepozidis
,
+14 authors
V. Georgoulias
Lung Cancer
2015
Corpus ID: 43377313
2014
2014
A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
C. Dittrich
,
Z. Pápai-Székely
,
+7 authors
J. von Pawel
European Journal of Cancer
2014
Corpus ID: 8263898
2014
2014
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung…
J. Yang
,
Jin-Hyoung Kang
,
+9 authors
Keunchil Park
European Journal of Cancer
2014
Corpus ID: 30521420
2013
2013
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer
Hongbin Chen
,
M. Modiano
,
+11 authors
H. Wakelee
British Journal of Cancer
2013
Corpus ID: 14114192
Background:This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non…
Expand
2013
2013
Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer.
M. Shtivelband
,
D. Spigel
,
+6 authors
C. Belani
2013
Corpus ID: 202814037
8095 Background: Bavituximab (B) is a monoclonal antibody against phosphatidylserine (PS) with a selective tumor vascular…
Expand
Highly Cited
2012
Highly Cited
2012
Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non…
Hee-Joung Kim
,
K. Lee
,
+9 authors
S. Kim
Lung Cancer
2012
Corpus ID: 41040384
Review
2011
Review
2011
Revisiting cutaneous adverse reactions to pemetrexed.
C. Piérard‐franchimont
,
P. Quatresooz
,
M. Reginster
,
G. Piérard
Oncology Letters
2011
Corpus ID: 8490575
Pemetrexed (Alimta®) is a multitargeted antifolate drug approved as a single agent or in combination with cisplatin for the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE